Department of Pediatrics, The Ohio State University College of Medicine and Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, USA.
Division of Nephrology and Hypertension, Nationwide Children's Hospital, Columbus, OH, USA.
J Nephrol. 2022 Jul;35(6):1679-1687. doi: 10.1007/s40620-022-01264-6. Epub 2022 Feb 15.
Hospitalized neonates are often treated with nephrotoxic medications, a known risk factor for acute kidney injury (AKI). Nephrotoxic medications and AKI, especially in periviable neonates, could be detrimental to nephrogenesis. Our objectives were to evaluate the prevalence of neonatal treatment with nephrotoxic medications and its relationship with AKI in in the first 28 days of life, and to delineate the associated demographics and diagnoses.
Multicenter retrospective analysis using the national Pediatric Hospital Information System database, including 49 pediatric hospitals. Neonates admitted within the first two postnatal days were included. Treatment with 37 nephrotoxic medications across demographics and clinical variables, and relationship with AKI were evaluated. AKI was determined by using the International Classification of Diseases codes.
Of 192,229 neonates, 74% were treated with at least one nephrotoxic medication. Incidence of AKI was significantly higher in the treated group (aRR 3.68 [95% CI: 2.85, 4.75]). The aRRs of treatment were increased in infants born < 32-week, and < 2000 g. Nephrotoxic medications were prescribed to 90-95% of neonates born ≤ 28-week gestational age. Most treatments (95-98%) occurred in the first 3 days. Intravascular aminoglycosides were the most frequent type; 28% of neonates were treated for ≥ 4 calendar days. Most common diagnoses were infections (25%) and patent ductus arteriosus (20%).
Neonatal treatment with nephrotoxic medications is common, especially among the smallest, most immature preterm neonates and demonstrates a need for initiatives to reduce neonatal exposure to these agents, when feasible. Across all gestational age categories, the prevalence of AKI is higher in the neonates treated with nephrotoxic drugs. The long-term effects of treatment with nephrotoxic medications and subsequent AKI on nephrogenesis and nephron endowment will need to be evaluated.
住院新生儿常接受肾毒性药物治疗,这是急性肾损伤(AKI)的已知危险因素。肾毒性药物和 AKI,尤其是在极早产儿中,可能对肾发生有害。我们的目的是评估新生儿在生命的头 28 天内接受肾毒性药物治疗的流行率及其与 AKI 的关系,并阐明相关的人口统计学和诊断。
使用国家儿科医院信息系统数据库进行多中心回顾性分析,包括 49 家儿科医院。纳入出生后前两天内入院的新生儿。评估了 37 种肾毒性药物在人口统计学和临床变量中的治疗情况及其与 AKI 的关系。AKI 通过使用国际疾病分类代码确定。
在 192229 名新生儿中,74%的新生儿接受了至少一种肾毒性药物治疗。治疗组 AKI 的发生率明显更高(调整后的比值比[aRR] 3.68 [95%置信区间:2.85,4.75])。出生时胎龄<32 周和体重<2000 克的婴儿治疗 aRR 增加。90-95%出生时胎龄≤28 周的新生儿接受了肾毒性药物治疗。大多数治疗(95-98%)发生在出生后前 3 天。血管内氨基糖苷类是最常见的类型;28%的新生儿接受了≥4 个日历天的治疗。最常见的诊断是感染(25%)和动脉导管未闭(20%)。
新生儿接受肾毒性药物治疗很常见,尤其是在最小、最不成熟的早产儿中,这表明需要采取措施减少新生儿接触这些药物,在可行的情况下。在所有胎龄类别中,接受肾毒性药物治疗的新生儿 AKI 的发生率更高。需要评估治疗肾毒性药物和随后 AKI 对肾发生和肾单位供应的长期影响。